UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

2315 A phase Ib study of the FGFR/VEGFR inhibitor dovitinib (D) combined with gemcitabine (G) and Capecitabine (C) in advanced pancreatic cancer patients

European journal of cancer (1990), 2015-09, Vol.51, p.S438-S438

2015

Link zum Volltext

Verfügbarkeit prüfen

3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S634-S634

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Link zum Volltext

Verfügbarkeit prüfen

9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

European journal of cancer (1990), 2011, Vol.47, p.S595-S595

2011

Link zum Volltext

Verfügbarkeit prüfen

EP06.02-02 Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S479-S480

2023

Link zum Volltext

Verfügbarkeit prüfen

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

Annals of oncology, 2023-10, Vol.34, p.S807-S807

2023

Link zum Volltext

Verfügbarkeit prüfen

381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

Annals of oncology, 2020-11, Vol.31, p.S1389-S1390

2020

Link zum Volltext

Verfügbarkeit prüfen

1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

Annals of oncology, 2020-09, Vol.31, p.S812-S812

2020

Link zum Volltext

Verfügbarkeit prüfen

1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2020-09, Vol.31, p.S819-S820

2020

Link zum Volltext

Verfügbarkeit prüfen

551 Functional characteristics of human epidermal growth factor receptor (EGFR) polymorphisms

European journal of cancer supplements, 2010, Vol.8 (7), p.175-175

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

Annals of oncology, 2005-11, Vol.16 (11), p.1811-1816

2005

Link zum Volltext

Verfügbarkeit prüfen

Farnesyl transferase inhibitors as anticancer agents

European Journal of Cancer, 2002-09, Vol.38 (13), p.1685-1700

2002

Link zum Volltext

Verfügbarkeit prüfen

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

The New England journal of medicine, 2020-09, Vol.383 (13), p.1207-1217

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)

Annals of oncology, 2016-10, Vol.27, p.vi167-vi167

2016

Link zum Volltext

Verfügbarkeit prüfen

Survie globale et analyses exploratoires par sous-groupes de l’étude de phase II CodeBreaK 100 évaluant le sotorasib chez des patients atteints d’un cancer du poumon non à petites cellules avec mutation KRAS p.G12 C, prétraité

Revue des maladies respiratoires actualités, 2022-01, Vol.14 (1), p.208-209

2022

Link zum Volltext

Verfügbarkeit prüfen

Évaluation de la résistance acquise au sotorasib dans le cancer colorectal (CCR) et le cancer bronchique non à petites cellules (CBNPC) avec mutation KRASG12C : analyse de biomarqueurs plasmatiques de l’étude CodeBreaK 100

Revue des maladies respiratoires actualités, 2023-01, Vol.15 (1), p.131

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Link zum Volltext

Verfügbarkeit prüfen

447PD - Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors

Annals of oncology, 2012-09, Vol.23, p.ix155-ix155

2012

Link zum Volltext

Verfügbarkeit prüfen

Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors

Annals of oncology, 2012-09, Vol.23, p.ix155

2012

Link zum Volltext

Verfügbarkeit prüfen

Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study

Annals of oncology, 2014-09, Vol.25, p.iv458

2014

Link zum Volltext

Verfügbarkeit prüfen

Dalotuzumab

Drugs of the future, 2010, Vol.35 (8), p.609

Dy, G.K.

2010

Link zum Volltext

Verfügbarkeit prüfen

Dalotuzumab

Drugs of the future, 2010-08, Vol.35 (8), p.609

Dy, G.K.

2010

Link zum Volltext

Verfügbarkeit prüfen

1300PBUPARLISIB (BKM120) IN PATIENTS WITH PI3K PATHWAY-ACTIVATED, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM THE BASALT-1 STUDY

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv458-iv459

2014

Link zum Volltext

Verfügbarkeit prüfen

Methods for improving efficiency in quality measurement: the example of pain screening

International journal for quality in health care, 2011-12, Vol.23 (6), p.657-663

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(27)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(9)
Life Sciences & Biomedicine
(7)
Female
(5)
Hematology, Oncology And Palliative Medicine
(5)
Humans
(5)
Biological And Medical Sciences
(4)
Aged
(3)
Antineoplastic Agents
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer
(3)
Male
(3)
Medical Sciences
(3)
Middle Aged
(3)
Oncology
(3)
Patients
(3)
Aged, 80 And Over
(2)
Animals
(2)
Antitumor Activity
(2)
Chemotherapy
(2)
Confidence Intervals
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

2315 A phase Ib study of the FGFR/VEGFR inhibitor dovitinib (D) combined with gemcitabine (G) and Capecitabine (C) in advanced pancreatic cancer patients

3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC)

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

EP06.02-02 Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

1411P Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)

381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)

551 Functional characteristics of human epidermal growth factor receptor (EGFR) polymorphisms

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

Farnesyl transferase inhibitors as anticancer agents

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)

Survie globale et analyses exploratoires par sous-groupes de l’étude de phase II CodeBreaK 100 évaluant le sotorasib chez des patients atteints d’un cancer du poumon non à petites cellules avec mutation KRAS p.G12 C, prétraité

Évaluation de la résistance acquise au sotorasib dans le cancer colorectal (CCR) et le cancer bronchique non à petites cellules (CBNPC) avec mutation KRASG12C : analyse de biomarqueurs plasmatiques de l’étude CodeBreaK 100

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

447PD - Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors

Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors

Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study

Dalotuzumab

Dalotuzumab

1300PBUPARLISIB (BKM120) IN PATIENTS WITH PI3K PATHWAY-ACTIVATED, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM THE BASALT-1 STUDY

Methods for improving efficiency in quality measurement: the example of pain screening

Suchergebnisse filtern